Genetic risk factors for type 2 diabetes mellitus and response to sulfonylurea treatment

被引：9

作者：

Swen, Jesse J. ^{[1
]}

Guchelaar, Henk-Jan ^{[1
]}

Baak-Pablo, Renee F. ^{[1
]}

Assendelft, Willem J. J. ^{[2
]}

Wessels, Judith A. M. ^{[1
]}

机构：

[1] Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, NL-2300 RC Leiden, Netherlands

[2] Leiden Univ, Med Ctr, Dept Publ Hlth & Primary Care, NL-2300 RC Leiden, Netherlands

来源：

PHARMACOGENETICS AND GENOMICS | 2011年 / 21卷 / 08期

关键词：

glibenclamide; gliclazide; glimepiride; pharmacogenetics; sulfonylureas; tolbutamide; type 2 diabetes mellitus; GENOME-WIDE ASSOCIATION; E23K VARIANT; POLYMORPHISMS; SUSCEPTIBILITY; KIR6.2; LOCI; HYPOGLYCEMIA; PREDICTION; INSULIN; KCNJ11;

D O I：

10.1097/FPC.0b013e3283478173

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Objective After the identification of type 2 diabetes mellitus (T2DM) risk alleles from genome-wide association studies, models have been developed to identify subjects at high risk to develop T2DM. We hypothesize that a panel of 20 repeatedly associated T2DM risk alleles influences response to sulfonylureas (SUs). Methods Two hundred and seven incident SU (tolbutamide, glibenclamide, glimepiride, gliclazide) users with T2DM were recruited from four primary care centers. A genetic risk score per patient was calculated based on the number of risk-alleles. With this score, patients were categorized into three predefined genetic risk groups. The effect of the genetic risk group on the achievement of stable SU dose, prescribed stable SU dose, and time to stable SU dose was analyzed. Results Carriers of more than 17 T2DM risk alleles had a 1.7-fold reduced likelihood to achieve stable SU dose (P = 0.044). No significant effect of the number of T2DM risk alleles on prescribed dose was found. Carriers of more than 17 T2DM risk alleles showed a marginally significant increased time to stable dose (hazard ratio: 0.81; 95% confidence interval, 0.75-1.01, P = 0.058). Conclusion T2DM risk alleles are associated with response to SUs in primary care T2DM patients. This suggests that individualization of T2DM treatment according to genetic profile may be an opportunity to improve clinical outcome. Pharmacogenetics and Genomics 21:461-468 (c) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

引用

页码：461 / 468

页数：8

共 48 条

[1]

[Anonymous], 2006, HUISARTS WET

[2]

Aquilante CL, 2010, EXPERT REV CARDIOVAS, V8, P359, DOI [10.1586/erc.09.154, 10.1586/ERC.09.154]

[3] Pharmacogenetic prediction of clozapine response [J].

Arranz, MJ ;

Munro, J ;

Birkett, J ;

Bolonna, A ;

Mancama, D ;

Sodhi, M ;

Lesch, KP ;

Meyer, JFW ;

Sham, P ;

Collier, DA ;

Murray, RM ;

Kerwin, RW .

LANCET, 2000, 355 (9215) :1615-1616

[4] Cytochrome P450 2C9*2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus [J].

Becker, M. L. ;

Visser, L. E. ;

Trienekens, P. H. ;

Hofman, A. ;

van Schaik, R. H. N. ;

Stricker, BHCh .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) :288-292

[5] Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea [J].

Becker, Matthijs L. ;

Aarnoudse, Albert-Jan L. H. J. ;

Newton-Cheh, Christopher ;

Hofman, Albert ;

Witteman, Jacqueline C. M. ;

Uitterlinden, Andre G. ;

Visser, Loes E. ;

Stricker, Bruno H. Ch. .

PHARMACOGENETICS AND GENOMICS, 2008, 18 (07) :591-597

[6] A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk [J].

Bouatia-Naji, Nabila ;

Bonnefond, Amelie ;

Cavalcanti-Proenca, Christine ;

Sparso, Thomas ;

Holmkvist, Johan ;

Marchand, Marion ;

Delplanque, Jerome ;

Lobbens, Stephane ;

Rocheleau, Ghislain ;

Durand, Emmanuelle ;

De Graeve, Franck ;

Chevre, Jean-Claude ;

Borch-Johnsen, Knut ;

Hartikainen, Anna-Liisa ;

Ruokonen, Aimo ;

Tichet, Jean ;

Marre, Michel ;

Weill, Jacques ;

Heude, Barbara ;

Tauber, Maithe ;

Lemaire, Katleen ;

Schuit, Frans ;

Elliott, Paul ;

Jorgensen, Torben ;

Charpentier, Guillaume ;

Hadjadj, Samy ;

Cauchi, Stephane ;

Vaxillaire, Martine ;

Sladek, Robert ;

Visvikis-Siest, Sophie ;

Balkau, Beverley ;

Levy-Marchal, Claire ;

Pattou, Francois ;

Meyre, David ;

Blakemore, Alexandra I. F. ;

Jarvelin, Marjo-Riita ;

Walley, Andrew J. ;

Hansen, Torben ;

Dina, Christian ;

Pedersen, Oluf ;

Froguel, Philippe .

NATURE GENETICS, 2009, 41 (01) :89-94

[7] Pharmacogenetics of glucose-lowering drug treatment - A Systematic review [J].

Bozkurt, Oezlem ;

de Boer, Anthonius ;

Grobbee, Diederick E. ;

Heerdink, Eibert R. ;

Burger, Huib ;

Klungel, Olaf H. .

MOLECULAR DIAGNOSIS & THERAPY, 2007, 11 (05) :291-302

[8] Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls [J].

Burton, Paul R. ;

Clayton, David G. ;

Cardon, Lon R. ;

Craddock, Nick ;

Deloukas, Panos ;

Duncanson, Audrey ;

Kwiatkowski, Dominic P. ;

McCarthy, Mark I. ;

Ouwehand, Willem H. ;

Samani, Nilesh J. ;

Todd, John A. ;

Donnelly, Peter ;

Barrett, Jeffrey C. ;

Davison, Dan ;

Easton, Doug ;

Evans, David ;

Leung, Hin-Tak ;

Marchini, Jonathan L. ;

Morris, Andrew P. ;

Spencer, Chris C. A. ;

Tobin, Martin D. ;

Attwood, Antony P. ;

Boorman, James P. ;

Cant, Barbara ;

Everson, Ursula ;

Hussey, Judith M. ;

Jolley, Jennifer D. ;

Knight, Alexandra S. ;

Koch, Kerstin ;

Meech, Elizabeth ;

Nutland, Sarah ;

Prowse, Christopher V. ;

Stevens, Helen E. ;

Taylor, Niall C. ;

Walters, Graham R. ;

Walker, Neil M. ;

Watkins, Nicholas A. ;

Winzer, Thilo ;

Jones, Richard W. ;

McArdle, Wendy L. ;

Ring, Susan M. ;

Strachan, David P. ;

Pembrey, Marcus ;

Breen, Gerome ;

St Clair, David ;

Caesar, Sian ;

Gordon-Smith, Katherine ;

Jones, Lisa ;

Fraser, Christine ;

Green, Elain K. .

NATURE, 2007, 447 (7145) :661-678

[9] Joint Effects of Common Genetic Variants on the Risk for Type 2 Diabetes in U. S. Men and Women of European Ancestry [J].

Cornelis, Marilyn C. ;

Qi, Lu ;

Zhang, Cuilin ;

Kraft, Peter ;

Manson, JoAnn ;

Cai, Tianxi ;

Hunter, David J. ;

Hu, Frank B. .

ANNALS OF INTERNAL MEDICINE, 2009, 150 (08) :541-W98

[10] Pharmacologic therapy for type 2 diabetes mellitus [J].

DeFronzo, RA .

ANNALS OF INTERNAL MEDICINE, 1999, 131 (04) :281-303

← 1 2 3 4 5 →